Evora Biosciences develops EVOGEX, a proprietary discovery platform which combine the therapeutic properties of exosomes and cell penetrating peptides.

Our off-the-shelf exosomes are engineered for improved efficacy against immuno-inflammatory diseases.

Evora Bioscience heralded as one of France’s top 15 biotechs to invest in.
Challenges Magazine – March 2022

EVOGEX is Evora’s proprietary therapeutic discovery platform, based on patent-protected peptide-engineering of exosomes.

The aim of EVOGEX is to significantly enhance key properties of exosomes, to improve efficacy of exosome-based therapeutic approaches in immuno-inflammatory diseases.

Primary target : digestive fistula healing

Digestive fistula can be life-impairing for patients, and are linked to a variety of conditions, such as Crohn’s Disease, or surgical procedures, such as weight-loss procedures like sleeve gastrectomies.

For complex cases, currently available therapeutic options for patients and clinicians are unsatisfactory. Our lead product EVOGEX-Digest aims to dramatically improve patient outcomes in several GI-related indications.

Exosomes : powerful, efficient and customizable

Exosomes are small biological particle secreted by cells, from which they inherit some key therapeutic properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells, while drastically simplifying logistics.

Compared to stem cells, exosome-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.

For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.

Lastly, exosomes are perfectly suited for engineering, which enables significant improvements of their targeting , cell penetrating and cargo delivery properties.


Hadrien Lanvin, MSc

Founder & CEO

Amanda Silva Brun, PharmD, PhD

Founder &  CSO

Anna Kostrzak, PhD

R&D Director

Scientific Founders

Amanda Silva Brun
PharmD, PhD

2021 CNRS Innovation Medal. Galenic pharmacy and exosomes expert. Multiple patents in the field of exosomes.

Prof. Gabriel Rahmi

Interventional endoscopy and digestive fistula expert.

Florence Gazeau

Nanoparticles and exosomes expert. Multiple patents in the field of exosomes.

Max Piffoux
MD-Fellow, PhD

Expert in therapeutics applications and high-yield exosomes production. Multiple patents in the field of exosomes.

Claire Wilhelm

CNRS Bronze Medal, exosomes and magnetic materials expert. Multple patents in the field of exosomes.

Partners & Ecosystem